<DOC>
	<DOCNO>NCT01537640</DOCNO>
	<brief_summary>Primary Objective : To determine compare pharmacokinetic ( PK ) profile 2 different SAR231893 ( REGN668 ) drug product administration single subcutaneous ( SC ) dose Secondary Objective : To determine compare safety tolerability 2 SAR231893 ( REGN668 ) drug product administration single SC dose</brief_summary>
	<brief_title>Comparison Pharmacokinetics Safety Two SAR231893 ( REGN668 ) Drug Products Healthy Subjects</brief_title>
	<detailed_description>The duration study subject 8-11 week break follow : - Screening : 2 21 day , - Treatment : 1 day ( 2 overnight stay study site ) , - Follow-up : 2 month dose .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Healthy male female subject 18 45 year age Exclusion criterion : Presence history drug hypersensitivity allergic disease History presence dermatological disorder Fever persistent chronic active recur infection require treatment within 4 week prior screen , history frequent recurrent infection Prior opportunistic infection within 6 month inclusion History presence listeriosis tuberculosis Any vaccination within 3 month ( 1 month influenza vaccine ) inclusion Any biologics give within 4 month inclusion Recent history parasitic infection travel parasitic endemic area within 6 month prior screen The information intend contain consideration relevant subject 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>